Dr. Namitha Kumar's Profile
MA - English, PhD (Psychology)
Her deepest passion is working on human experience of disability. She holds a PhD in Psychology. She is also interested in experiences of chronic and genetic illnesses.
Written / Edited / Medically Reviewed
An important signaling protein that regulates the production of hemoglobin was discovered. Blocking this protein can increase fetal hemoglobin production and deliver therapeutic benefits to Sickle Cell Disease (SCD) and Beta-Thalassemia.
Unexpected DNA changes and off-target mutations in CRISPR-Cas9 edited mouse and human cells were reported in recent research. CRISPR-Cas9 has been heralded as the gene editing tool of choice to correct genetic disorders.
Familial risk of heart failure: There is limited understanding of genetic mechanisms leading to heart failure. Though the cardiomyopathies are fairly well documented, we need more studies on the heritability of heart failure. Understanding this will go a long way in improving public health.
Monogenic hereditary disorders are largely responsible for child mortality and morbidity. However, intrauterine genetic editing could correct the genetic defect and thereby cure the disease in the fetus.
World Sickle Cell Day falls on 19 June each year. Sickle Cell Disease (SCD) is the most common genetic disorder in the world. World Sickle Cell Day was earmarkedby the United Nations officially in 2008.